Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 701–800 of 1,004
Capodanno, D., Milluzzo, R. P., & Angiolillo, D. J. (2019) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944719893274 · Cited by 80
Patient blood management during cardiac surgery: Do we have enough evidence for clinical practice?
Ranucci, M., Aronson, S., Dietrich, W., Dyke, C., Hofmann, A., Karkouti, K., Levi, M. M., Murphy, G. J., Sellke, F. W., Shore-Lesserson, L. J., et al. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.04.007 · Cited by 83
“Prasugrel hydrochloride is a recently approved thienopyridine for patients with ACS that has a rapid onset of action and a potent, more consistent, and long-lasting antiplatelet effect.(84) The combination of prasugrel hydrochloride and aspirin demonstrated superior efficacy to that of clopidogrel bisulfate and aspiri…”
BackgroundCurrent State and Novel Approaches of Antiplatelet Therapy
Metharom, P., Berndt, M. C., Baker, R. I., & Andrews, R. K. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303413 · Cited by 89
Stramba‐Badiale, M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq094 · Cited by 87
Cuisset, T., Grosdidier, C., Loundou, A., Quilici, J., Loosveld, M., Camoin‐Jau, L., Pankert, M., Beguin, S., Lambert, M., Morange, P., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.04.009 · Cited by 79
Clinical implications of clopidogrel resistance
Miguel, A. D., Ibáñez, B., & Badimón, J. J. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-01-0049 · Cited by 76
“Bleeding complications were more frequent among old patients (>75 years), those with low weight (<60 kg) and in patients with a history of stroke and/or transient ischemic attack (61).”
BackgroundPerceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndromes
Chew, D. P., Ge, J., Parsonage, W. A., Kerkar, P. G., Sulimov, V. A., Horsfall, M. J., Mattchoss, S., & for the Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndrome Patients (PREDICT) Study Investigators (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000072 · Cited by 83
Dynamic TIMI Risk Score for STEMI
Amin, S., Morrow, D. A., D, E. B. M., Sloan, S., Contant, C., Murphy, S. A., & Antman, E. M. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.003269 · Cited by 76
“The score was then validated using a database of STEMI patients in Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel (TRITON)-TIMI 38, a clinical trial comparing prasugrel with clopidogrel in moderateto high-risk acute coronary syndrome patients scheduled for PCI.(14)…”
BackgroundMethodInfluentialSelf-citationGuha, S., Sethi, R., Ray, S., Bahl, V. K., Shanmugasundaram, S., Kerkar, P. G., Ramakrishnan, S., Yadav, R. K., Chaudhary, G. K., Kapoor, A., et al. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.03.006 · Cited by 89
Novel Antiplatelet Therapies for Atherothrombotic Diseases
Majithia, A., & Bhatt, D. L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310955 · Cited by 89
Alexopoulos, D. K., Xanthopoulou, I., Deftereos, S. G., Sitafidis, G., Kanakakis, J., Hamilos, M. I., Angelidis, C., Petousis, S., Stakos, D., Parissis, H., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.10.010 · Cited by 75
Urological Surgery and Antiplatelet Drugs After Cardiac and Cerebrovascular Accidents
Eberli, D., Chassot, P., Sulser, T., Samama, C. M., Mantz, J., Delabays, A., & Spahn, D. R. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.02.2391 · Cited by 75
3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY
Gualandro, D., Yu, P., Caramelli, B., Marques, A., Calderaro, D., Fornari, L. S., Pinho, C., Feitosa, A. K. N., Polanczyk, C. A., Rochitte, C. E., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170140 · Cited by 90
Small, D. S., Kothare, P. A., Yuen, E., Lachno, D. R., Li, Y. G., Winters, K. J., Farid, N. A., Ni, L., Jakubowski, J. A., Salazar, D. E., et al. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0737-1 · Cited by 75
arenhorst, C., James, S. K., Brandt, J. T., Jakubowski, J. A., Winters, K. J., Wallentin, L. C., Erlinge, D., Braun, O. Ö., Johnell, M., & Siegbahn, A. G. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-05-0313 · Cited by 75
“These features of prasugrel may contribute to the observed reduction in thrombotic events in patients with acute coronary syndromes but also be related to the raised risk of bleeding observed in this phase Ib study as well as in the recent phase III trial (14).”
BackgroundFloyd, C. N., Passacquale, G., & Ferro, A. (2012) · Clinical Pharmacokinetics · doi:10.2165/11630740-000000000-00000 · Cited by 79
“In a pharmacogenetic analysis of the TRITONTIMI 38 trial, in the prasugrel group there was no association found between negative cardiovascular outcomes and the presence of the genetic variants either inMDR1 (also referred to as ABCB1) or CYP2C19, in contrast to clopidogrel.([21,58])”
BackgroundMethodResultInfluentialSmall, D. S., Wrishko, R. E., Ernest, C. S., Ni, L., Winters, K. J., Farid, N. A., Li, Y. G., Brandt, J. T., Salazar, D. E., Borel, A. G., et al. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01068.x · Cited by 75
“In a phase 3 study (TRITON-TIMI 38) in patients with acute coronary syndromes (ACS) with planned percutaneous coronary intervention (PCI), prasugrel given as a 60-mg loading dose (LD) followed by daily 10-mg maintenance doses (MD), co-administered with aspirin, significantly reduced rates of ischaemic events when comp…”
BackgroundHansson, E. C., Hakimi, C. S., Åström-Olsson, K., Hesse, C., Wallén, H., Dellborg, M., Albertsson, P., & Jeppsson, A. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet339 · Cited by 78
Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment
Giosia, P. D., Passacquale, G., Petrarca, M., Giorgini, P., Marra, A. M., & Ferro, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.025 · Cited by 85
Sequential proteome alterations during genesis and progression of colon cancer
Gustafsson, M., Bruch, H.-P., Franz�n, B., Ried, T., Bergmann, T., Auer, G., J�rnvall, H., Roblick, U. J., Hirschberg, D., Habermann, J. K., et al. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4049-4 · Cited by 81
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Magnani, G., Bonaca, M. P., Braunwald, E., Dalby, A. J., Fox, K. A. A., Murphy, S. A., Nicolau, J. C., Ophuis, T. O., Scirica, B. M., Špinar, J., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001505 · Cited by 79
Self-citationKang, J., & Kim, H.-S. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0166 · Cited by 79
Blood cells: an historical account of the roles of purinergic signalling
Burnstock, G. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9462-7 · Cited by 76
“Ticagrelor and prasugrel are more potent P2Y12 receptor inhibitors compared to clopidogrel and both have been shown to demonstrate improved clinical effects in preventing myocardial infarction [359, 360].”
Gouya, G., Arrich, J., Wolzt, M., Huber, K., Verheugt, F. W. A., Gurbel, P. A., Pirker-Kees, A., & Siller-Matula, J. M. (2013) · Stroke · doi:10.1161/strokeaha.113.002590 · Cited by 83
Dual antiplatelet therapy for secondary prevention of coronary artery disease
Degrauwe, S., Pilgrim, T., Aminian, A., Noble, S., Meier, P., & Iglesias, J. F. (2017) · Open Heart · doi:10.1136/openhrt-2017-000651 · Cited by 84
“Intense P2Y 12 receptor inhibition for patients with ACS undergoing PCI has been shown to improve clinical outcomes in RCTs comparing DAPT regimens with clopidogrel versus placebo, 50 prasugrel versus clopidogrel, 51 or ticagrelor versus clopidogrel.”
BackgroundMethodInfluentialBokeriya, L. A., & Dm, A. (2016) · Cardiosomatics · doi:10.26442/cs45210 · Cited by 108
Urban, P. M., Abizaid, A., Chevalier, B., Greene, S., Meredith, I. T., Morice, M., & Pocock, S. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.008 · Cited by 73
Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified
Serebruany, V. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-12-0807 · Cited by 73
Non–ST-Segment Acute Coronary Syndromes
Hedayati, T., Yadav, N., & Khanagavi, J. (2017) · Cardiology Clinics · doi:10.1016/j.ccl.2017.08.003 · Cited by 86
Narata, A. P., Amelot, A., Bibi, R. E., Herbreteau, D., Angoulvant, D., Gruel, Y., & Janot, K. (2018) · Neurosurgery · doi:10.1093/neuros/nyy002 · Cited by 74
External Validation of the DAPT Score in a Nationwide Population
Ueda, P., Jernberg, T., James, S. K., Alfredsson, J., Erlinge, D., Ömerovic, E., Persson, J., Ravn‐Fischer, A., Tornvall, P., Svennblad, B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.023 · Cited by 78
“Other factors that could affect the generalizability of the DAPT score and its decision rule to new settings include how the trade-off between ischemic and bleeding risk is influenced by the type of P2Y12 inhibitor used (2,21,22), and weights assigned to bleeding and ischemic events based on the harm (e.”
BackgroundBonello, L., Angiolillo, D. J., Aradi, D., & Sibbing, D. (2018) · Circulation · doi:10.1161/circulationaha.118.032078 · Cited by 82
Akkaif, M. A., Daud, N. A. A., Sha’aban, A., Ng, M. L., Kader, M. A. S. A., Noor, D. A. M., & Ibrahim, B. (2021) · Molecules · doi:10.3390/molecules26071987 · Cited by 86
“However, the study found that patient age was the primary determinant of outcome after PCI, [141,142], especially when using P2Y12 receptor inhibitors during and after PCI [143,144].”
Verdoia, M., Pergolini, P., Rolla, R., Nardin, M., Schaffer, A., Barbieri, L., Marino, P. N., Bellomo, G., Suryapranata, H., & Luca, G. D. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13177 · Cited by 78
Hobl, E., Reiter, B., Schoergenhofer, C., Schwameis, M., Derhaschnig, U., Kubica, J., Stimpfl, T., & Jilma, B. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12550 · Cited by 79
Cuisset, T., Frère, C., Quilici, J., Gaborit, B., Castelli, C., Poyet, R., Bali, L., Morange, P., Alessi, M., & Bonnet, J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.06.007 · Cited by 73
Verdoia, M., Schaffer, A., Barbieri, L., Cassetti, E., Piccolo, R., Galasso, G., Marino, P. N., Sinigaglia, F., & Luca, G. D. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000052 · Cited by 73
Goggs, R. A. N., Blais, M., Brainard, B. M., Chan, D. L., deLaforcade, A. M., Rozanski, E. A., & Sharp, C. R. (2019) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12801 · Cited by 86
“37 These guidelines are based on a wealth of high-quality evidence resulting from large-scale randomized controlled trials.(38-49) Although some of these guidelines may be applicable to small animals, it is clear that the underlying physiology,(50-53) the overall burden of disease and the most frequently associated di…”
BackgroundAntiplatelet agents for chronic kidney disease
Palmer, S. C., Micco, L. D., Razavian, M., Craig, J. C., Perkovic, V., Pellegrini, F., Jardine, M., Webster, A. C., Zoungas, S., & Strippoli, G. F. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008834.pub2 · Cited by 86
Angiolillo, D. J., & Ferreiro, J. L. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70010-4 · Cited by 75
Physician response to implementation of genotype‐tailored antiplatelet therapy
Peterson, J., Field, J., Unertl, K. M., Schildcrout, J. S., Johnson, D., Shi, Y., Danciu, I., Cleator, J. H., Pulley, J., McPherson, J., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.331 · Cited by 75
“We also specifically tracked outcomes among patients with a bleeding risk, defined as specific risks for prasugrel at the time of stent placement (age 75 years old, weight <60 kg, history of cerebrovascular disease, or with concomitant use of anticoagulation).(21,23)”
MethodAlexopoulos, D., Xanthopoulou, I., Deftereos, S. G., Hamilos, M. I., Sitafidis, G., Kanakakis, J., Pentara, I., Vavouranakis, M., Davlouros, P. A., Hahalis, G. N., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13316 · Cited by 78
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations
Sambu, N., & Curzen, N. P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03955.x · Cited by 77
Capodanno, D., & Angiolillo, D. J. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.113.001150 · Cited by 79
Targeting Outpatient Drug Safety: Recommendations of the Dutch HARM-Wrestling Task Force
Herwaarden, M. F. W., Kramers, C., Sturkenboom, M., van den Bemt, P. M. L. A., & Smet, P. A. G. M. D. (2012) · Drug Safety · doi:10.2165/11596000-000000000-00000 · Cited by 90
Abu‐Assi, E., Raposeiras‐Roubín, S., Lear, P., Cabanas‐Grandío, P., Girondo, M. R., Rodríguez-Cordero, M., Pereira-López, E., Romaní, S. G., González-Cambeiro, C., Álvarez, B. Á., et al. (2012) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872612453924 · Cited by 77
Potent P2Y 12 Inhibitors in Men Versus Women
Lau, E. S., Braunwald, E., Murphy, S. A., Wiviott, S. D., Bonaca, M. P., Husted, S., James, S. K., Wallentin, L. C., Clemmensen, P. M., Roe, M. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.028 · Cited by 77
Self-citationLee, F., Sun, C., Sung, P., Chen, K., Chua, S., Sheu, J., Chung, S., Chai, H., Chen, Y., Huang, T., et al. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12489 · Cited by 72
New Directions in Antiplatelet Therapy
Ferreiro, J. L., & Angiolillo, D. J. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.966176 · Cited by 79
Marsousi, N., Daali, Y., Fontana, P., Reny, J., Ancrenaz, V., Calmy, A., Rudaz, S. L., Desmeules, J. A., & Samer, C. F. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0637-6 · Cited by 74
Sudlow, C. L. M., Mason, G., Maurice, J. B., Wedderburn, C. J., & Hankey, G. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001246.pub2 · Cited by 72
Abrignani, M. G., Gatta, L., Gabrielli, D., Milazzo, G., Francesco, V. D., Luca, L. D., Francese, M., Imazio, M., Riccio, E., Rossini, R., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.11.014 · Cited by 87
Hamatani, Y., Ogawa, H., Uozumi, R., Iguchi, M., Yamashita, Y., Esato, M., Chun, Y., Tsuji, H., Wada, H., Hasegawa, K., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-1245 · Cited by 74
Singh, J., Zeller, W. E., Zhou, N., Hategen, G., Mishra, R. K., Polozov, A., Yu, P., Onua, E., Zhang, J., Zembower, D. E., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb8002094 · Cited by 74
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
Alexopoulos, D. K., Xanthopoulou, I., Mavronasiou, E., Stavrou, K., Siapika, A., Tsoni, E., & Davlouros, P. A. (2013) · Diabetes Care · doi:10.2337/dc12-2510 · Cited by 74
Lala, A., Berger, J. S., Sharma, G. K., Hochman, J. S., Braithwaite, R. S., & Ladapo, J. A. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12059 · Cited by 72
Rinfret, S., Rodés‐Cabau, J., Bagur, R., Déry, J., Dorais, M., Larose, É., Barbeau, G. R., Gleeton, O., Nguyen, C. M., Noël, B. M., et al. (2013) · Heart · doi:10.1136/heartjnl-2012-303004 · Cited by 70
Cangrelor: a review on pharmacology and clinical trial development
Franchi, F., Rollini, F., Muñiz‐Lozano, A., Cho, J. R., & Angiolillo, D. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.837701 · Cited by 78
Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03644.x · Cited by 75
Pharmacodynamic effects during the transition between cangrelor and prasugrel
Schneider, D. J., Seecheran, N. A., Raza, S. S., Keating, F. K., & Gogo, P. B. (2014) · Coronary Artery Disease · doi:10.1097/mca.0000000000000158 · Cited by 70
Chandrasekhar, J., Baber, U., Sartori, S., Faggioni, M., Aquino, M. B., Kini, A. S., Weintraub, W. S., Rao, S. V., Kapadia, S. R., Weiss, S. A., et al. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26606 · Cited by 70
“These findings in men are aligned with randomized data from the TRITON TIMI-38 trial, attributed to superior metabolism and greater ADP receptor suppression by prasugrel compared with clopidogrel [18].”
BackgroundMethodResultInfluentialTargeting Platelets for the Treatment of Cancer
Elaskalani, O., Berndt, M., Falasca, M., & Metharom, P. (2017) · Cancers · doi:10.3390/cancers9070094 · Cited by 77
Crescente, M., Menke, L., Chan, M. V., Armstrong, P. C. J., & Warner, T. D. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14196 · Cited by 83
“Aspirin is commonly given in combination with antagonists of ADP, acting at P2Y12 receptor, such as clopidogrel, prasugrel or ticagrelor (Bhatt, 2009; Gargiulo et al., 2016; Investigators TCIUaTPRET, 2001; Patrono et al., 2011; Wallentin et al., 2009; Windecker et al., 2014; Wiviott et al., 2007).”
BackgroundTime course, predictors and clinical implications of stent thrombosis following primary angioplasty
Dirksen, M. T., Spaulding, C. M., Kelbæk, H., Schalij, M. J., Thuesen, L., van der Hoeven, B., Vink, M. A., Kaiser, C. A., Musto, C., Chechi, T., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0092 · Cited by 69
“Given the high rate of ST after pPCI in STEMI, regardless whether a BMS or first generation DES was used, future studies are needed to evaluate the potential safety benefits from new generation DES (18) as well as the role of optimal peri-procedural antithrombotic therapy (19, 20) and prolonged DAT to reduce subacute…”
BackgroundClinical Application of Cardiovascular Pharmacogenetics
Voora, D., & Ginsburg, G. S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.067 · Cited by 75
“The need for pharmacogenomics in clinical practice is underscored, for example, by the improved ischemic outcomes with newer platelet P2RY12 receptor inhibitors which also have higher risk of adverse events compared to clopidogrel (1,2).”
Thomas, M. R., Morton, A. C., Hossain, R., Chen, B., Luo, L., Shahari, N. N. B. M., Hua, P., Beniston, R., Judge, H. M., & Storey, R. F. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-02-0102 · Cited by 73
“This was a crossover study of 11 aspirin-treated patients with prior history of STEMI treated with PPCI, for which prasugrel and morphine had been previously administered.”
BackgroundInfluentialCurrent and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
Jourdi, G., Lordkipanidzé, M., Philippe, A., Bachelot‐Loza, C., & Gaussem, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313079 · Cited by 80
“Prasugrel and ticagrelor are thus preferred in these patients in association with aspirin [105,106].”
BackgroundCapodanno, D., & Angiolillo, D. J. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.10.023 · Cited by 76
Abu‐Assi, E., López-López, A., Salvado, V. G., Diéguez, A. R., Peña, C., Bouzas‐Cruz, N., Raposeiras‐Roubín, S., Abumuaileq, R. R.-Y., García‐Acuña, J. M., & González‐Juanatey, J. R. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.06.015 · Cited by 74
Fox, K. A. A., Carruthers, K. F., Steg, P. G., Avezum, Á., Granger, C. B., Montalescot, G., Goodman, S. G., Gore, J. M., Quill, A., Eagle, K. A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp499 · Cited by 69
Self-citationZhou, X., Huang, Y., Khalil, M. K., Wiktor, D. M., van Giezen, J. J. J., Penn, M. S., & Wang, K. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-12-0823 · Cited by 69
“3/2010 (43), but treatment with the agent, which like other thienopyridines is an irreversible P2Y12 receptor antagonist, was also associated with a significantly increased risk of major bleeding, including life-threatening and fatal bleeding.”
BackgroundHazarbasanov, D., Velchev, V., Finkov, B., Postadzhiyan, A., Kostov, E., Rifai, N., & Aradi, D. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0684-z · Cited by 71
Rossen, J. D., Chalouhi, N., Wassef, S. N., Thomas, J. P., Abel, T. J., Jabbour, P. M., Kung, D. K., & Hasan, D. M. (2012) · Journal of neurosurgery · doi:10.3171/2012.8.jns12185 · Cited by 69
Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel
Kernéis, M., Silvain, J., Abtan, J., Cayla, G., O’Connor, S. A., Barthélémy, O., Vignalou, J.-B., Beygui, F., Brugier, D., Martin, R., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.09.012 · Cited by 70
Self-citationSerebruany, V. L., Cherala, G., Williams, C. D., Surigin, S., Booze, C., Kuliczkowski, W., & Atar, D. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.10.012 · Cited by 71
“Moreover, no load clopidogrel regimen was associated with absolute mortality reduction, saving 119 lives in patients with post myocardial infarction,(7) the benefit never seen with more potent antiplatelet strategies including platelet GP IIb/IIIa inhibitors(8) or prasugrel.(9) There is a growing concern that low resp…”
Kim, S., Choi, J.-H., Kang, M., Cha, J., & Huh, J.-T. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4551 · Cited by 69
Gherli, R., Mariscalco, G., Dalén, M., Onorati, F., Perrotti, A., Chocron, S., Verhoye, J., Gulbins, H., Reichart, D., Svenarud, P. K., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3028 · Cited by 73
A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease
Warlo, E. M. K., Arnesen, H., & Seljeflot, I. (2019) · Thrombosis Journal · doi:10.1186/s12959-019-0197-5 · Cited by 73
Broussalis, E., Killer‐Oberpfalzer, M., McCoy, M. R., Harrer, A., Trinka, E., & Kraus, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.005 · Cited by 76
Ferroni, P., Vazzana, N., Riondino, S., Cuccurullo, C., Guadagni, F., & Davì, G. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4324 · Cited by 68
“Prasugrel has also been shown to be more effective than clopidogrel in ACS patients undergoing PCI, but with more bleeding (323) and has been approved in the United States and Europe for this kind of patients.”
Angiolillo, D. J., & Ferreiro, J. L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70010-5 · Cited by 68
Capodanno, D., & Angiolillo, D. J. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002301 · Cited by 71
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD
Arora, S., Shemisa, K., Vaduganathan, M., Qamar, A., Gupta, A., Garg, S. K., Kumbhani, D. J., Mayo, H., Khalili, H., Pandey, A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.470 · Cited by 75
From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes
Szummer, K. E., Jernberg, T., & Wallentin, L. C. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.531 · Cited by 77
Intracranial Hemorrhage During Dual Antiplatelet Therapy
Ha, A. C. T., Bhatt, D. L., Rutka, J. T., Johnston, S. C., Mazer, C. D., & Verma, S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.048 · Cited by 81
Enfermedad cardiovascular en el anciano
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.001 · Cited by 95
“Aunque los pacientes de edad (cid:2) 75 an˜os suponen entre el 32 y el 38% de los sujetos que sufren un sı´ndrome coronario agudo sin elevacio´n del ST (SCASEST) en los estudios de registros, son so´lo un 18% de la poblacio´n en estudio en los ensayos clı´nicos 71 .”
BackgroundAspirin and clopidogrel: efficacy and resistance in diabetes mellitus
Angiolillo, D. J., & Suryadevara, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.12.001 · Cited by 79
Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials
Eapen, Z. J., Tang, W. H. W., Felker, G. M., Hernandez, A. F., Mahaffey, K. W., Lincoff, A. M., & Roe, M. T. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966150 · Cited by 68
The Perioperative Management of Treatment With Anticoagulants and Platelet Aggregation Inhibitors
Schlitt, A., Jámbor, C., Spannagl, M., Gogarten, W., Schilling, T., & Zwißler, B. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0525 · Cited by 91
Management of Patients With NSTE-ACS
Rodríguez, F., & Mahaffey, K. W. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.599 · Cited by 80
Gupta, R., Moore, J. M., Griessenauer, C. J., Adeeb, N., Patel, A. S., Youn, R., Poliskey, K., Thomas, A. J., & Ogilvy, C. S. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.09.013 · Cited by 68
Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists
Schilling, U., Dingemanse, J., & Ufer, M. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00864-4 · Cited by 72
Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines
Kietaibl, S., Ferrandis, R., Godier, A., Llau, J., Lobo, C., Macfarlane, A. J., Schlimp, C. J., Vandermeulen, E., Volk, T., von Heymann, C., et al. (2022) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001600 · Cited by 289
Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention
Åkerblom, A., James, S. K., Koutouzis, M., Lagerqvist, B., Stenestrand, U., Svennblad, B., & Oldgren, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.093 · Cited by 70
High platelet reactivity and clinical outcome – Fact and fiction
Sibbing, D., Byrne, R. A., Bernlochner, I., & Kastrati, A. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0040 · Cited by 72
“Notwithstanding, it seems unlikely that all patients will benefit from more potent antiplatelet drugs as the value of antithrombotic treatment is determined by the balance between the prevention of ischaemic complications and the induction of bleeding (9, 10); the latter is – not surprisingly – a major shortcoming of…”
BackgroundInfluentialCuisset, T., Hamilos, M. I., Sarma, J., Sarno, G., Wyffels, E., Vanderheyden, M., Barbato, E., Bartúnek, J., Bruyne, B. D., & Wijns, W. C. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.054 · Cited by 67
Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence
Cacciatore, S., Spadafora, L., Bernardi, M., Galli, M., Betti, M., Perone, F., Nicolaio, G., Marzetti, E., Martone, A. M., Landi, F., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165233 · Cited by 84
“Among P2Y12 receptor inhibitors, prasugrel is generally not recommended in patients over 75 since the TRITON-TIMI 38 trial reported excess bleeding risk, resulting in a neutral net clinical benefit in older patients [66].”
BackgroundWhite, W. B., Grady, D. G., Giudice, L. C., Berry, S. M., Zborowski, J., & Snabes, M. C. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.09.021 · Cited by 72
Grosdidier, C., Quilici, J., Loosveld, M., Camoin‐Jau, L., Moro, P.-J., Saut, N., Gaborit, B., Pankert, M., Cohen, W., Lambert, M., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.013 · Cited by 66
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.